Butyrylcholinesterase (BChE) has become a critical target in Alzheimer’s disease (AD) research due to its role in acetylcholine (ACh) hydrolysis and its link to β-amyloid (Aβ) deposition, which worsens disease progression. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.